What Is hCG?

1. How does hCG work in men?

The normal reproductive pathway runs from the brain to the testes: the hypothalamus releases GnRH, the pituitary releases LH and follicle-stimulating hormone (FSH), and the testes respond. LH stimulates testosterone production. FSH helps support sperm production.

hCG acts at the LH receptor, bypassing the need for the pituitary to supply that signal. It can therefore stimulate responsive testes even when LH is suppressed. The EAU male infertility guideline describes gonadotropin treatment for hypogonadotropic hypogonadism, where upstream hormone stimulation is insufficient. Some patients require FSH as well as hCG to induce sperm production.

Primary testicular failure is a different problem: the testes are failing despite stimulation. Adding an LH-like signal cannot be assumed to correct it. Before comparing hormone products, establish where the pathway is impaired.

The Pregnyl label includes selected cases of male hypogonadotropic hypogonadism and ovulation induction in appropriately treated infertile women. Those indications do not extend to every low testosterone reading, gym goal or retail research vial.

2. hCG and TRT: blood testosterone vs testosterone inside the testes

Exogenous testosterone means testosterone supplied from outside the body. Through hormonal feedback, it can suppress LH and FSH. Blood testosterone can look excellent while testosterone inside the testes falls sharply.

Coviello and colleagues’ 2005 randomized study enrolled 29 healthy men. All received testosterone enanthate; groups also received placebo or different hCG doses for three weeks. Researchers sampled fluid from the testes to measure intratesticular testosterone directly.

These doses describe an experiment, not a personal regimen. The result establishes a dose response in a local hormone measurement. Three weeks of preserved intratesticular testosterone cannot establish long-term sperm production, pregnancy rates or an ideal TRT add-on dose.

3. Does hCG preserve fertility on TRT?

Hsieh and colleagues’ 2013 study reviewed 26 men receiving testosterone plus hCG. No participant became azoospermic, meaning no sperm were detected in the ejaculate, and nine contributed to a partner’s pregnancy. Mean follow-up was 6.2 months; some observations extended beyond one year.

That is encouraging clinical evidence, with limits. The study was retrospective, small and lacked a testosterone-only control group. Nine pregnancies among 26 men is not a treatment success rate for everyone: conception depends on partner factors, timing and whether a couple is trying.

The AUA/ASRM guideline advises against testosterone monotherapy for men interested in current or future fertility. It allows clinicians to consider hCG, selective estrogen receptor modulators (SERMs), aromatase inhibitors or combinations for infertile men with low testosterone, with a conditional recommendation based on low-quality evidence.

Adding hCG does not remove the need to discuss fertility before TRT. If pregnancy is the goal, semen analysis supplies information that testosterone, libido and perceived testicular size cannot.

4. What do the human studies support?

These papers answer different questions. Preserving a hormone concentration, maintaining semen parameters and recovering sperm production after testosterone exposure are separate outcomes.

None of these studies measured a dependable muscle-building or longevity benefit in healthy adults. They also cannot tell a reader how much libido, energy or strength will improve. A study needs to measure the outcome being advertised.

5. hCG for PCT and recovery after testosterone

Post-cycle therapy, or PCT, is the term used in bodybuilding for attempts to restore hormonal function after anabolic steroid use. Clinical treatment of testosterone-related infertility is more specific: it starts with a diagnosis and follows sperm and hormone measurements.

In Wenker’s 2015 series, 49 men had no sperm or extremely low counts while using testosterone. Treatment combined hCG with other drugs chosen by the clinician. Forty-seven had documented return of sperm or improved counts; average time to sperm recovery was 4.6 months.

There was no untreated comparison, and the accompanying medicines varied. The study cannot isolate hCG’s effect or establish how much faster treatment worked than withdrawal alone. The 95.9% figure describes the study’s sperm endpoint, not a pregnancy rate, complete hormonal recovery or a universal PCT success rate.

An on-treatment testosterone increase also cannot establish recovery of pituitary LH production. Sustained function after treatment ends needs its own assessment. Weeks of better symptoms and months of sperm recovery operate on different timelines.

6. hCG vs clomiphene, kisspeptin and HGH

The point of action helps explain why these compounds are not interchangeable.

The AUA/ASRM guidance discusses SERMs and hCG as options in selected infertile men, rather than ranking one as a universal winner. The kisspeptin studies reviewed in our linked guide do not establish it as an hCG replacement. Combining several compounds also makes a change in symptoms or laboratory results harder to attribute.

7. hCG side effects and estrogen

The Pregnyl prescribing information reports injection-site reactions, headache, mood-related symptoms, fluid retention and gynecomastia. It also reports severe allergic reactions. The label does not provide a dependable percentage risk for each effect in a healthy person adding hCG to TRT.

Estradiol belongs in the clinical discussion alongside testosterone, especially if breast symptoms develop. Starting an aromatase inhibitor based on a forum’s target number adds another intervention; a clinician needs to interpret symptoms, measurements and the whole regimen together.

In ovarian stimulation, the Ovidrel label warns about ovarian hyperstimulation syndrome (OHSS), including serious fluid shifts and vascular complications. Severe pelvic pain, rapid weight gain or breathing difficulty during fertility treatment need urgent assessment. Male TRT discussions do not describe the risk profile of an ovulation-trigger protocol.

8. hCG dosage, half-life and IU

There is no single hCG dose that covers male hypogonadism, fertility preservation, infertility recovery and ovulation induction. They involve different diagnoses, products and endpoints. The study doses above explain published findings; copying one does not establish that it fits another person’s problem.

The Ovidrel label reports a terminal half-life of about 29 hours after subcutaneous administration in studied women. Absorption, formulation and population limit how directly that number transfers to other settings. A half-life curve cannot predict sperm recovery or select an injection interval.

IU means international units of biological activity. Milliliters measure liquid volume. Syringe “units” are volume markings for a particular syringe. Treating those numbers as interchangeable creates a dosing error. Use the prescribed product’s concentration and instructions; a milligram-based peptide calculator does not automatically apply to hCG.

Storage and time after mixing also depend on the exact preparation. Keep the pharmacy instructions with the vial rather than borrowing a storage window from another brand or a peptide forum.

9. Does the hCG diet work for weight loss?

The FDA’s assessment finds no substantial evidence that hCG adds weight loss beyond calorie restriction, redistributes fat or reduces hunger during dieting. hCG is not approved for weight loss.

Many hCG diets pair the product with about 500 calories a day. That restriction can cause weight loss regardless of hCG, while introducing risks including gallstones, electrolyte imbalance and irregular heartbeat. A falling scale reading cannot identify the injection or drops as the cause.

The diet claim also has no support from the male fertility studies above. Preserving testosterone inside the testes does not demonstrate fat loss, appetite suppression or muscle preservation during a severe calorie deficit.

10. What should you measure before calling it a benefit?

The Endocrine Society guideline requires compatible symptoms and consistently low testosterone for a hypogonadism diagnosis, with repeat morning fasting testing. LH and FSH help distinguish testicular from hypothalamic or pituitary causes. A single disappointing result after poor sleep cannot settle a treatment decision.

For fertility, discuss semen testing and your conception timeline. For symptoms, record the specific problem: low desire, erectile difficulty and fatigue are different outcomes. Report adverse effects even when testosterone rises.

A useful treatment record includes the exact product, prescribed amount, injection dates, other hormones or medicines, blood-draw timing, laboratory results and symptoms. Bring the original reports to follow-up. Changing TRT, hCG and an estrogen-modifying drug together makes a before-and-after testosterone result difficult to interpret.

11. hCG FAQ

• What does hCG stand for?

  Human chorionic gonadotropin. It is a reproductive hormone with LH-like activity and is also the hormone measured by pregnancy tests.

• Does hCG increase testosterone in men?

  It can stimulate testosterone production when the testes can respond. The cause of low testosterone matters; primary testicular failure and inadequate pituitary signaling are different problems.

• Does hCG guarantee fertility on TRT?

  No. A small retrospective study found preserved semen parameters, but it cannot establish a guarantee or an individual success rate. Fertility assessment needs semen testing rather than a testosterone result alone.

• Is hCG the same as HGH?

  No. hCG is human chorionic gonadotropin, associated with reproductive signaling. HGH is human growth hormone, associated with growth and the IGF-1 pathway.

• Is hCG a proven post-cycle therapy?

  Clinicians use hCG-based treatment in selected cases of testosterone-related infertility. Published combination-treatment results do not establish a universal self-directed PCT schedule or prove sustained hormonal recovery after treatment ends.

• How long does hCG stay in your system?

  The Ovidrel label reports an approximately 29-hour terminal half-life after subcutaneous administration in studied women. Product, route and population matter; that figure does not specify an injection schedule or the end of every hormonal effect.

• Can hCG cause gynecomastia?

  Yes. Gynecomastia, or breast-tissue enlargement, is a reported adverse effect in the Pregnyl label. New breast symptoms warrant clinical assessment.

• Does hCG burn fat or reduce hunger?

  FDA finds no substantial evidence that hCG improves weight loss beyond calorie restriction or reduces hunger on a restricted diet. Drops and homeopathic products do not establish a weight-loss benefit.

• Are hCG IU the same as syringe units?

  No. IU describes biological activity; syringe markings measure volume. The relationship depends on the prepared concentration and syringe type. A peptide calculator using milligrams cannot supply an hCG conversion without validated product information.

12. Sources